Autonomix Medical, Inc. is a medical device company developing precision nerve-targeted therapies to transform treatment of peripheral nervous system diseases.

The Company’s first-in-class platform technology utilizes a proprietary, catheter-based microchip sensing array that we believe surpasses other sensing technology available today and sets a new standard in neural signal detection. For the first time ever, the sensing technology enables the ability to detect and differentiate neural signals by combining ultra-high sensitivity with data processing performed directly at the point of detection. Once target nerves are identified, Autonomix uses its proprietary radio frequency (RF) ablation technology to kill targeted nerves, enabling a precision guided sense, treat and verify approach to addressing a number of disease categories from chronic pain management to hypertension and cardiology.

Autonomix is initially developing its precision nerve-targeted technology for the treatment of pain associated with pancreatic cancer. Initial results from the Company’s ongoing first-in-human study have shown clinically meaningful and durable pain reduction in the initial phase of the study. By delivering targeted ablation transvascularly through the vessel wall, Autonomix has demonstrated success in pancreatic cancer pain which opens up the possibility of transformative denervation treatment across a number of disease categories including hypertension, chronic pain, cardiology, pulmonology, and gastroenterology through a single, first-in-class platform technology.